NASDAQ:PPH VanEck Pharmaceutical ETF (PPH) Price, Holdings, & News $91.26 +0.92 (+1.02%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$92.02 +0.75 (+0.83%) As of 02/21/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrends About VanEck Pharmaceutical ETF (NASDAQ:PPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PPH alerts:Sign Up Key Stats Today's Range$90.51▼$91.4850-Day Range$85.24▼$91.2652-Week Range$84.48▼$99.51Volume1.33 million shsAverage Volume366,764 shsMarket Capitalization$569.46 millionAssets Under Management$655.58 millionDividend Yield1.86%Net Expense Ratio0.36%Aggregate RatingModerate Buy ETF OverviewThe VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.Read More… VanEck Pharmaceutical ETF ExpensesTypePPHHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.35%0.57%0.56%0.51%0.53%Other Expenses0.01%0.30%0.50%0.47%0.53%Total Expense0.36%0.70%0.72%0.67%0.71%Fee Waiver0.00%-0.45%-0.50%-0.32%-0.56%Net Expense0.36%0.61%0.62%0.60%0.60% Receive PPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VanEck Pharmaceutical ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address PPH ETF News HeadlinesVanEck Vectors Pharmaceutical ETF declares quarterly distribution of $0.4110December 27, 2024 | msn.comThe Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNROctober 17, 2024 | finance.yahoo.comShocking Elon Move: Bigger than DOGE?After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recent DOGE moves… What Elon Musk is about to do next could not only shock the world… But also put an extra $30,000 a year in your pocket.February 22, 2025 | Brownstone Research (Ad)Diversified Exposure To The Weight Loss Drug MarketOctober 10, 2024 | seekingalpha.comPharma Stocks Losing Ground After A Remarkable Rally, Downgrading PPHOctober 3, 2024 | seekingalpha.comAbbVie stock analysis: Rinvoq and Skyrizi are big catalystsOctober 1, 2024 | msn.comSee More Headlines PPH ETF - Frequently Asked Questions How have PPH shares performed this year? VanEck Pharmaceutical ETF's stock was trading at $86.28 on January 1st, 2025. Since then, PPH stock has increased by 5.8% and is now trading at $91.26. View the best growth stocks for 2025 here. Who are VanEck Pharmaceutical ETF's major shareholders? Top institutional shareholders of VanEck Pharmaceutical ETF include J.Safra Asset Management Corp (4.20%), Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (3.18%), Miller Investment Management LP (3.05%) and Thrivent Financial for Lutherans (2.45%). How do I buy shares of VanEck Pharmaceutical ETF? Shares of PPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VanEck Pharmaceutical ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that VanEck Pharmaceutical ETF investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Fund Details IssuerVan Eck Fund NameVanEck Pharmaceutical ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:PPH Inception Date12/20/2011 Fund ManagerHao-Hung Peter Liao, Guo Hua Jason Jin WebN/A Phone14089961010Fund Focus Asset ClassEquity BenchmarkMarket Vectors US Listed Pharmaceutical 25 Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionGlobal Number of Holdings25 Fund Statistics Assets Under Management$554.43 million Average Daily Volume$347,506.30 Discount/Premium0.01% Administrator, Advisor and Custodian AdministratorVan Eck Associates Corporation AdvisorVan Eck Associates Corporation CustodianState Street Bank and Trust Company DistributorVan Eck Securities Corporation Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerIMC Options OptionableOptionable Options Volume33 Put Options26 Call Options7 Short Interest2,850,000 shs Miscellaneous Outstanding Shares6,240,000Beta0.72 Creation Unit50,000 Creation Fee$500.00 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report Top 10 PPH HoldingsEli Lilly and Company (NYSE:LLY)Holding Weight: 14.71%Johnson & Johnson (NYSE:JNJ)Holding Weight: 7.15%AbbVie (NYSE:ABBV)Holding Weight: 7.04%Novo Nordisk A/S (NYSE:NVO)Holding Weight: 6.50%Novartis AG ADRHolding Weight: 5.39%AstraZeneca (NASDAQ:AZN)Holding Weight: 5.37%Sanofi (NASDAQ:SNY)Holding Weight: 5.03%Cencora (NYSE:COR)Holding Weight: 4.84%GSK (NYSE:GSK)Holding Weight: 4.74%McKesson (NYSE:MCK)Holding Weight: 4.68%Full Holdings DetailsPPH Sector ExposurePPH Industry Exposure This page (NASDAQ:PPH) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Pharmaceutical ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share VanEck Pharmaceutical ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
